(MedPage Today) — A single dose of synthetic psilocybin significantly reduced symptoms of treatment-resistant depression in a 6-week phase III trial, said developer Compass Pathways.
In an opinion piece, Allen Frances, MD, chair of the DSM-IV…
Source link : https://www.medpagetoday.com/psychiatry/generalpsychiatry/116246
Author :
Publish date : 2025-06-25 18:27:00
Copyright for syndicated content belongs to the linked Source.
